CD95 _ FAS
- Known as:
- CD95 _ Fas Cell Surface Death Receptor
- Catalog number:
- AM08165BT-N
- Product Quantity:
- 100 Tests
- Category:
- -
- Supplier:
- ACR
- Gene target:
- CD95 _ FAS
Related genes to: CD95 _ FAS
- Gene:
- FAS NIH gene
- Name:
- Fas cell surface death receptor
- Previous symbol:
- FAS1, APT1, TNFRSF6
- Synonyms:
- CD95, APO-1
- Chromosome:
- 10q23.31
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-25
- Date modifiied:
- 2019-04-23
Related products to: CD95 _ FAS
Related articles to: CD95 _ FAS
- This study used scRNA-seq to explore the underlying mechanisms of decidual natural killer cells affecting recurrent miscarriage (RM). - Source: PubMed
Fu BinbinWang Huijing - Nitro-fatty acids (NO-FAs) are potent electrophiles that react with nucleophilic residues in proteins (cysteines, histidines and lysines) via a process known as nitroalkylation. This reversible post-translational modification (PTM) functions as a selective signalling mechanism by modulating the structure, transport, and catalysis of target proteins. In the present work, in vivo nitroalkylated proteins targets by nitro-oleic acid (NO-OA), nitro-linoleic acid (NO-LA) and NO-Ln have been identified in different Arabidopsis development, including the seed, vegetative, generative and senescence stages. The results reveal that nitroalkylation is a PTM that occurs throughout the development of Arabidopsis, primarily during the vegetative and generative stages. This modification predominantly affects proteins involved in energy metabolism, redox coenzymes and stress responses. Although all three NO-FAs interact with the three amino acids mentioned, cysteine is the primary target. However, its adducts are significantly more labile and redox-sensitive than those formed with histidine or lysine. Overall, these results suggest that nitroalkylation constitutes a reversible post-translational modification linked to the redox state. This regulation could participate in modulating the plasticity of energy flow, contributing to maintaining homoeostasis throughout the life cycle and resilience to environmental stress. Data are available via ProteomeXchange with identifier PXD060471. - Source: PubMed
Publication date: 2026/10/04
Aranda-Caño LorenaValderrama RaquelChaki MouniraBegara-Morales Juan CarlosPedrajas José RafaelMelguizo ManuelMoret MatínBombarely AurelianoLuque FranciscoBarroso Juan Bautista - Drug therapies targeting vasculature in metastatic cancer have not been highly effective and are therefore currently limited to an adjunctive role, such as in combination regimens. The development of novel, more effective therapeutic strategies with new mechanisms of action is therefore greatly needed. In a previous study, we reported a lipid nanoparticle (LNP)-based vascular-disrupting strategy utilizing cyclic RGD peptide-modified LNPs encapsulating small interfering RNA against Fas ligand (cRGD-LNP/siFasL). We combined this strategy for selective targeting of tumor endothelial cells with stimulator of interferon genes (STING) agonist-loaded LNPs (STING-LNPs). Here, we have demonstrated the potential of such combination therapy in treating lung metastases. We found that cRGD-LNPs accumulated in the vasculature within tumor colonies in the lung. A combination of cRGD-LNP/siFasL and STING-LNP induced significant antitumor effects in mouse models of Renca and 4T1 lung metastases. Moreover, this combination therapy reduced the vasculature within tumor colonies, with no obvious change in the surrounding normal lung tissue, indicating preferential vascular disruption. These findings demonstrate that the combination therapy exerts antitumor activity against lung metastases through tumor vascular disruption, indicating that such treatment is potentially a potent disrupter of the vascularity in metastatic tumors. - Source: PubMed
Ueda TomokiEndo RikitoSato YusukeHarashima HideyoshiYamada YumaNakamura Takashi - The mannan-conjugated birch pollen polymerised allergoid EP-088_T502 has previously been shown to reduce allergic symptoms and anti-allergic medication use during the birch pollen season. This confirmatory phase III trial aimed to evaluate the efficacy, safety, tolerability, and immunologic effects of EP-088_T502 administered as eight subcutaneous injections over six pre-seasonal treatment visits. - Source: PubMed
Raskopf EstherPassamera SofiaKlimek LudgerPfaar OliverNeuhof ChristianRybachuk AnnaKatzke NadineSahin HacerAllekotte SilkeMösges RalphDay LauraSubiza José LuisCasanovas MiguelCuevas MandyDel Pozo Sandra - Glioblastoma (GBM) remains a highly lethal brain tumor with limited therapeutic options and pervasive resistance to standard treatments. Cyclin-dependent kinases (CDKs), key regulators of cell cycle progression and transcription, are frequently dysregulated in GBM and contribute to tumor pathogenesis. - Source: PubMed
Publication date: 2026/10/02
Kaps PhilippHieltscher Anne SophieAuditore AndreaKamper ChristophNelz Sophie-CharlotteHeskamp JacquelineMeißner PaulWolff AnnabellRichter KatharinaBrandstetter JakobGrabarczyk PiotrTroschke-Meurer SaschaHinz BurkhardWittig FelixDubinski DanielGessler FlorianFreiman Thomas MStählke SusanneFicht Philipp-KjellBoeckmann LarsPolley ChristianClassen Carl-FriedrichJunghanss ChristianMaletzki Claudia